Results 221 to 230 of about 87,373 (338)

Sperm protein 17 (Sp17) in multiple myeloma: opportunity for myeloma-specific donor T cell infusion to enhance graft-versus-myeloma effect without increasing graft-versus-host disease risk [PDF]

, 2001
Maurizio Chiriva‐Internati, Zhiqing Wang, Yuying Xue, Klaus Bumm, Amy B. Hahn, Seah H. Lim   +5 more
openalex   +1 more source

Role of Histone Deacetylase and Inhibitors in Cardiovascular Diseases

Cell Proliferation, EarlyView.
HDACs play an important role in the occurrence and development of cardiovascular diseases, such as myocardial hypertrophy, hypertension, and atherosclerosis. HDAC inhibitors have broad prospects for the treatment of CVD, and different HDAC subtypes can act through different mechanisms.
Li‐Ying Zhang, Yue‐Yue Wang, Ri Wen, Tie‐Ning Zhang, Ni Yang   +4 more
wiley   +1 more source

Prognostic impact of dynamic changes of type I melanoma antigen gene proteins CT7 (<i>MAGE-C1/CT7</i>) transcripts in multiple myeloma. [PDF]

Front Med (Lausanne)
Dou X, Wang F, Chen H, Chen Y, Wen L, Liu Y, Ruan G, Zhao X, Huang X, Gale RP, Lu J.   +10 more
europepmc   +1 more source

Protein kinase C δ and η isoenzymes control the shedding of the interleukin 6 receptor α in myeloma cells [PDF]

, 2001
Wilfrid Thabard, M. Collette, Régis Bataille, Martine Amiot   +3 more
openalex   +1 more source

Tumour Cell Size Control and Its Impact on Tumour Cell Function

Cell Proliferation, EarlyView.
The regulatory mechanism of the size of tumour cells and its impact on the functions of tumour cells, as well as a summary of potential therapeutic targets for the corresponding mechanisms. ABSTRACT Cell size is an important component of cell morphological characteristics.
Min Zhou, Mei Zhou, Yang Jin
wiley   +1 more source

Exploring the role of circulating proteins in multiple myeloma risk: a Mendelian randomization study. [PDF]

Sci Rep
Lee MA, Burley KL, Hazelwood EL, Moore S, Lewis SJ, Goudswaard LJ.   +5 more
europepmc   +1 more source

Antisense inhibition of macrophage inflammatory protein 1-α blocks bone destruction in a model of myeloma bone disease [PDF]

, 2001
Sun Jin Choi, Yasuo Oba, Yair Gazitt, Melissa Alsina, Jose Cruz, Judith L. Anderson, G. David Roodman   +6 more
openalex   +1 more source

PROTEINS IN MULTIPLE MYELOMA

Journal of Biological Chemistry, 1953
Frank W. Putnam, Bernard Udin
openaire   +3 more sources

Sensitization of Non‐M3 Acute Myeloid Leukemia Blasts to All‐Trans Retinoic Acid by the LSD1 Inhibitor Tranylcypromine: TRANSATRA Phase I Study

European Journal of Haematology, EarlyView.
ABSTRACT The treatment of elderly, nonfit acute myeloid leukemia (AML)/MDS patients with relapsed/refractory (R/R) disease remains challenging. As histone demethylase LSD1 (KDM1A) is a rational therapeutic target in AML, we conducted a phase I trial (“rolling‐six design”) with the LSD1 inhibitor tranylcypromine (TCP, dose levels [DL] 20, 40, 60, 80 mg ...
Michael Kruszewski, Claudia Schmoor, Tobias Berg, Usama‐Ur Rehman, Marcus Schittenhelm, Katharina Götze, Andrea Kündgen, Caroline Pabst, Tobias Ma, Anna Frey, Julia Stomper, Dietmar Pfeifer, Eric Metzger, Johannes Jung, Kevin Moschallski, Johanna Thomas, Gesine Bug, Justus Duyster, Manfred Jung, Roland Schüle, Ralph Wäsch, Olga Grishina, Michael Lübbert   +22 more
wiley   +1 more source

A Rare Type of Myeloma: A Case of Monoclonal IgD-Lambda. [PDF]

Cureus
Kaya R, Kocabıyık AB, Kurtoğlu E, Karakuş V.   +3 more
europepmc   +1 more source